1. Home
  2. INDP vs MNDR Comparison

INDP vs MNDR Comparison

Compare INDP & MNDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INDP
  • MNDR
  • Stock Information
  • Founded
  • INDP 2000
  • MNDR 2016
  • Country
  • INDP United States
  • MNDR Singapore
  • Employees
  • INDP N/A
  • MNDR N/A
  • Industry
  • INDP Biotechnology: Pharmaceutical Preparations
  • MNDR
  • Sector
  • INDP Health Care
  • MNDR
  • Exchange
  • INDP Nasdaq
  • MNDR Nasdaq
  • Market Cap
  • INDP 10.2M
  • MNDR 10.1M
  • IPO Year
  • INDP N/A
  • MNDR 2024
  • Fundamental
  • Price
  • INDP $0.84
  • MNDR $0.32
  • Analyst Decision
  • INDP Strong Buy
  • MNDR
  • Analyst Count
  • INDP 2
  • MNDR 0
  • Target Price
  • INDP $8.50
  • MNDR N/A
  • AVG Volume (30 Days)
  • INDP 25.3K
  • MNDR 2.0M
  • Earning Date
  • INDP 03-12-2025
  • MNDR 10-29-2024
  • Dividend Yield
  • INDP N/A
  • MNDR N/A
  • EPS Growth
  • INDP N/A
  • MNDR N/A
  • EPS
  • INDP N/A
  • MNDR N/A
  • Revenue
  • INDP N/A
  • MNDR $13,968,535.00
  • Revenue This Year
  • INDP N/A
  • MNDR $188,831.77
  • Revenue Next Year
  • INDP N/A
  • MNDR $76.44
  • P/E Ratio
  • INDP N/A
  • MNDR N/A
  • Revenue Growth
  • INDP N/A
  • MNDR 77.38
  • 52 Week Low
  • INDP $0.81
  • MNDR $0.23
  • 52 Week High
  • INDP $3.10
  • MNDR $29.50
  • Technical
  • Relative Strength Index (RSI)
  • INDP 39.07
  • MNDR N/A
  • Support Level
  • INDP $0.86
  • MNDR N/A
  • Resistance Level
  • INDP $1.06
  • MNDR N/A
  • Average True Range (ATR)
  • INDP 0.08
  • MNDR 0.00
  • MACD
  • INDP 0.00
  • MNDR 0.00
  • Stochastic Oscillator
  • INDP 12.80
  • MNDR 0.00

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

About MNDR Mobile-health Network Solutions Class A Ordinary Shares

Mobile-health Network Solutions is a company engaged in providing telehealth solutions in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application. It provides services on its MaNaDr platform, which is accessible via mobile application and website. The MaNaDr platform is a platform designed and created by doctors, for doctors and users, equipped with services like consultations with doctors, e-commerce pharma store, and others. The company's operating segments are Telemedicine and other services which is also its key revenue generating segment, and Sale of medicine and medical devices. Geographically, it derives revenue from Singapore.

Share on Social Networks: